All Posts in Category: Uncategorized

U.S. Stem Cell to focus on and expand in-clinic therapies

Sunrise, FL – June 19, 2017 – (OTC:USRM) U.S. Stem Cell, Inc., a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, announces an aggressive plan to expand an additional 12 stem cell treatment centers and clinics in the US.  US Stem Cell has been in discussions with the FDA regarding Regenerative Medicine Advanced Therapy (RMAT) Designation for the Myocell product and at this time, the company has decided not to further invest in RMAT Designation and instead invest and focus on our in-clinic therapies for patients.

According to the 21st Century Cures Act, within one year of enactment, the FDA must issue draft guidance clarifying how the FDA will evaluate devices used in the recovery, isolation, or delivery of regenerative advanced therapies. Until this guidance document is published, it is unclear how this regulation will affect the MyoCell program. Until then, U.S. Stem Cell will focus on opening new clinics around the country to better serve patients in need.  In addition to the original Sunrise clinic (that has successfully treated hundreds of patients and generated over $2m in revenues in the past 12 months alone), recent clinic openings include Miami and Palm Beach, Florida.  Upcoming openings include Dallas, Texas (thanks in part to the early adoption of patient rights by the State of Texas), Chicago, Atlanta and Denver—as well as other clinics in the northeast and the west coast.

To be clear, U.S. Stem Cell will focus on our revenue generating programs that are treating patients NOW–which have successfully helped over 7000 patients thus far.  Our company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world.  In addition to our efforts at US Stem Cell Training and VetBiologics, our focus will be expanding and opening additional clinics throughout the U.S. to offer these cutting edge technologies to more patients.

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Read More

U.S. Stem Cell, Inc. Reports Continued Positive Results for Q1 2017

Sunrise, FL – May 3, 2017 – U.S. STEM CELL, Inc., a Florida corporation, a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending March 31, 2017:

  • Revenue up by 62% from $710,000 in Q1 2016 to $1.15M in Q1 2017
  • Gross profit up by 45.6% from $556,000 in Q1 2016 to $810,000 in Q1 2017
  • Cash Flow is positive Q1 2017 at $268,000 compared to Q1 2016 at ($62,000)
  • All debt-to-equity convertible notes have been either fully paid or converted as of March 31, 2017.

“We are very pleased with the 2017 improvements in operations and balance sheet performance,” said Mike Tomás, President & CEO of U.S. Stem Cell, Inc. “We are progressing with our principal strategic business initiatives which include growing top line revenues and pursuing new business opportunities for exponential growth.”

U.S. Stem Cell, Inc. continues to make a positive impact on the lives of patients treated using its procedures. This year we hope to continue our accomplishments and value for both patients and shareholders.

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

 

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

 

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Read More

U.S. STEM CELL RELEASES POSITIVE 2016 FINANCIAL RESULTS

 Sunrise, FL – March 15, 2017 – U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, is pleased to announce the following results from operations for the year ending December 31, 2016.

“U.S. Stem Cell, Inc. continues to increase revenue, decrease liabilities and decrease operating expenses,” said Mike Tomás, President and CEO of U.S. Stem Cell, Inc. “As a world leader in stem cell research and development for degenerative conditions, we are excited about the industry’s future and dedicated to making a positive impact in our patients’ lives.”

Working with physician partners to offer over 30 protocols to patients, U.S. Stem Cell, Inc. is increasing business opportunities by expanding its services, treatments and therapies both inside and outside the United States.

Financial highlights from 2016 include:

  • Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
  • Current liabilities down by $1.9M or 23.8% from $8.0M in 2015 to $6.1M in 2016
  • Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
  • Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
  • And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015

Operating results for the year ending December 31, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2017.

VIEW PDF HERE

 

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

Read More

Greg Knutson joins U.S. Stem Cell, Inc.’s Board of Directors

Sunrise, FL – March 7, 2017 – U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, is pleased to announce that Greg Knutson, the Manager of NorthStar Biotech, LLC, has joined the Board of Directors of U.S. Stem Cell, Inc.

“We are very pleased that Greg Knutson, a longtime supporter of the U.S. Stem Cell family of companies, has agreed to join our Board and assist us to continue with our recent technological advances and financial accomplishments,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. A longtime U.S. Stem Cell shareholder and supporter, Knutson brings more than 30 years of business and financial experience to the organization.  During his entrepreneurial career, Knutson founded Concrete Specialists, Inc. and continues to serve as its President; is the founder and current President of Sunwood Properties; and is the founder and Managing Partner of G&G Land Development, LLC.

Demonstrating a progressive step forward, Knutson joins the Board of Directors just as the two companies amicably settled a legal dispute related to NorthStar’s preferred shares.

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

 Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

 

Read More

U.S. Stem Cell Inc. Announces Launch of US Stem Cell Middle East

Sunrise, FL – November 16, 2016 – U.S. STEM CELL, INC., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to announce an agreement with Kuwait-based High Rising Group to launch U. S. Stem Cell Middle East.

U.S. Stem Cell, Inc. has recently signed a new licensing agreement with High Rising Group to open and operate regenerative medicine clinics throughout the Middle East. Patients suffering from chronic conditions including neurological, autoimmune, cardiovascular, COPD, and orthopedic ailments will now have access to stem cell therapy and other alternative medical treatments at any of our partner’s clinics in Dubai, Kuwait, Qatar, Bahrain, UAE, Saudi Arabia, Jordan and Egypt.

U.S. Stem Cell Middle East will offer regenerative treatment options to patients, based on U.S. Stem Cell, Inc. products and technologies like MyoCell, AdipoCell, and our Platelet Rich Plasma (PRP) method. U.S. Stem Cell, Inc. is hopeful that our stem cell therapies will transform the lives of patients worldwide.

“We at U.S. Stem Cell corporate are very happy and excited to partner with Ali Al Obaid and High Rising Group Company, said Mike Tomás, President and CEO of US Stem Cell Inc. “This partnership and licensing agreement will allow us to reach patients all over the world with our groundbreaking regenerative therapies. We believe that our innovative stem cell solutions can hopefully change the lives of those suffering from degenerative diseases in the Middle East.”

Managing Director of High Rising Group, Ali Al Obaid further stated “We are proud to bring first world regenerative medicine technologies to the Middle East via Kuwait and Dubai. After extensive research, we believe that US Stem Cell is the right partner to help our patients in the Middle East.”

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

Read More

U.S. Stem Cell, Inc. Reports Positive Results for Q3 2016

Sunrise, FL – November 9, 2016 – U.S. STEM CELL, INC., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to highlight the following results from operations for the quarter ending September 30, 2016:

• Current liabilities down $734,000 or 9.5% from $7.69M in Q3 2015 to $6.96M in Q3 2016
• Revenue up by 31% to from $557,000 in Q3 2015 to $729,000 in Q3 2016
• Net loss improved 17% from $264,000 in Q3 2015 to $219,000 in Q3 2016
• Cash used in operating activities down $322,000 or 84% from $384,000 in Q3 2015 to $62,000 in Q3 2016

“U.S. Stem Cell, Inc. continues to surpass its quarter-over-quarter business and financial performance,” stated Mike Tomas, President and CEO of U.S. Stem Cell Inc. “This is our best year yet so far. We have become a world leader in the research of new treatments for patients with degenerative conditions and continue to develop novel protocols for their care. This passion moves us to continue to work hard to strengthen the health of our business and expand our care to more countries and more patients in need.”

Operating results for the three and six months ended September 30, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016.

VIEW PDF HERE

About U.S. Stem Cell, Inc.

 

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

 

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

 

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

 

Read More

U.S. Stem Cell, Inc. Reports Positive Results for Q2 2016

Sunrise, FL – August 3, 2016 – U.S. STEM CELL, INC., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending June 30, 2016:

  • Revenue up by 20% from $565K in Q2 2015 to $678K in Q2 2016.
  • Current liabilities down $2.7 million or 33% from $8.2M in Q2 2015 to $5.7M in Q2 2016.
  • Gross Margin improved from 41% in 2015 to 62% in 2016.
  • Cash used in operating activities decreased ($481K) or 74% from $646K in Q2 2015 to $165K in Q2 2016
  • Working capital deficit improved by $2.5 million or 31.3% from $8M in Q2 2015 to $5.5M in Q2 2016
  • Net loss improved 46% from $480K in Q2 2015 to $259K in Q2 2016

“U.S. Stem Cell, Inc. continues to improve in its quarter-over-quarter P&L and balance sheet performance,” stated Mike Tomas, President and CEO of U.S. Stem Cell Inc. “Our mission to make a real and positive impact in the lives of the patients we are treating fuels our excitement for the future. We have become a world leader in the research of new treatments for patients with degenerative conditions and, with our physician partners, have jointly developed more than 30 protocols for their care. This passion moves us to continue to work hard to strengthen the health of our business and expand our care to more patients in need.”

Operating results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2016.

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.

Read More

U.S. Stem Cell, Inc. Reports Positive Results for Q1 2016

Sunrise, FL – May 5, 2016 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending March 31, 2016:

  • Revenues increased $221,000 (45%) from $490,000 in Q1 2015 to $711,000 in Q1 2016,
  • Gross margins, primarily due to in-house versus subcontracted lab kit construction, increased to 78% in Q1 2016 from 40% in Q1 2015,
  • Net operating loss decreased ($794,000) (98%) from ($808,000) in Q1 2015 to ($14,000) in Q1 2016,
  • Overall net loss decreased ($685,000) (65%) from ($1,048,000) in Q1 2015 to ($363,000) in Q1 2016. The decrease is attributable to higher gross margins and a decrease in marketing and general and administrative expenses,
  • Cash used in operating activities decreased ($322,000) (84%) from ($384,000) in Q1 2015 to ($62,000) in Q1 2016. On a cash accounting basis, the Company generated $6,000 in positive cash flows, and
  • The Company’s current liabilities and working capital deficit remained, for the most part, constant from Q1 2015 to Q1 2016.

“U.S. Stem Cell, Inc. continues to improve in its quarter-over-quarter P&L and balance sheet performance,” stated Mike Tomas, President and CEO of U.S. Stem Cell Inc. “Our mission to make a real and positive impact in the lives of the patients we are treating fuels our excitement for the future. As awareness of our successful patient treatment outcomes expands, we look forward to all of our performance indicators turning positive. We thank our shareholders for the long-standing support and we look forward to reporting on our future successes.”

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.

Read More

Dr. William P. Murphy delivers Keynote Address at the Academy of Regenerative Practices

Sunrise, FL – February 9, 2016 – US STEM CELL, Inc. (OTCQB:USRM) – The chairman of the board of directors of US Stem Cell Inc, Dr. William P. Murphy, Jr., delivered the keynote address at the 2nd annual Academy of Regenerative Practices (www.regenerativeacademy.com) in Ft. Lauderdale, Florida this past weekend. A medical pioneer and founder of Cordis Corporation (now a Johnson & Johnson company), Dr Murphy is a medical doctor and inventor of medical devices including collaborating on a flexible sealed blood bag used for blood transfusions as well as patents for inventing the physiologic pace maker and the artificial kidney. He is the son of the American physician William Parry Murphy who shared the Nobel Prize in Physiology for Medicine in 1934, and Harriett Adams, the first licensed female dentist in Massachusetts.

Read More

U.S. Stem Cell Now Trading USRM; Completes Financing Transaction

Sunrise, FL – December 4, 2015 – US STEM CELL, Inc. (OTC: USRM) (f/k/a Bioheart, Inc.) a Florida corporation, a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce the completion of its name change with its new trading symbol – USRM. Additionally, the Company has completed a financing transaction with Magna Equities II, LLC (“Magna”).

Read More

U.S. Stem Cell Announces Positive Results for Traumatic Brain Injury (TBI) Patients

Sunrise, FL – December 3, 2015 – U.S. STEM CELL, Inc. (OTC: USRM), a Florida corporation, a leader in the regenerative medicine/cellular therapy industry, developer of novel autologous cell therapies, and provider of physician based stem cell therapies to human and animal patients, is pleased to announce that it has successfully completed five physician based treatments of traumatic brain injury (TBI) patients. The five patients, who received stromal vascular fraction from adipose tissue delivered intrathecally, have been treated over the past 12 months at the US Stem Cell Clinic located in Sunrise, FL

Read More

U.S. Stem Cell, Inc. Reports Positive Results for 3Q 2015

Sunrise, FL – November 5, 2015 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending September 30, 2015:

Read More

U.S. Stem Cell, Inc. (f/k/a/ Bioheart, Inc.) Receives FINRA Approval for Reverse Split and Name Change

Sunrise, FL – November 4, 2015 – U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce that it has received approval, effective today, from the Financial Industry Regulatory Authority (“FINRA”) to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of its Common Stock. In connection with the Company’s reverse stock split, FINRA has assigned the Company a new stock symbol, BHRTD. The Company’s stock will be quoted as BHRTD through December 2, 2015, and thereafter, the trading symbol will be USRM (OTC Markets), reflecting the new name of the Company. The new CUSIP number is 90350U100. Additional information on the above transaction and name change can be found in our November 4, 2015 Form 8-K filing. Current stock certificates may be exchanged for new certificates by contacting the Company’s transfer agent, Continental Stock Transfer & Trust Company at:

Read More

US STEM CELL (Bioheart) Announces Insiders Intend to Purchase Company Common Stock in the Open Market

SUNRISE, FL / ACCESSWIRE / September 17, 2015 / US STEM CELL, Inc. (in transition from Bioheart, Inc. (BHRT.OB)) – announces today that “insiders” led by Dr. William P. Murphy, Jr., Chairman and Mike Tomas, President and CEO, intend to purchase, in the open market, up to 5% of the issued and outstanding Common Stock of the Company. The planned insider purchases are subject to customary restrictions based upon any of the participant’s knowledge of material non-public information and are further subject to federal securities disclosure rules. As the planed insider purchases are to be executed by individuals, US STEM CELL cannot guarantee the number of shares to be purchased or the time frame in which these shares will be bought in the open market.

Read More

For Immediate Release: Bioheart and Ascyrus Medical Execute Investment Agreement

Sunrise, FL – March 19, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB) and Ascyrus Medical, LLC, a Florida Limited Liability Corporation are pleased to announce that they have entered into an investment agreement. The investment agreement provides for Bioheart to obtain a consolidating ownership stake in Ascyrus Medical upon the achievement of certain business milestones. Bioheart has through June 30, 2015 to meet its milestone obligations.

Read More